Use of anakinra in severe COVID-19: A case report.

Authors :: Filocamo G
Mangioni D
Tagliabue P
Aliberti S
Costantino G
Minoia F
Bandera A
Source :: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2020 Jul; Vol. 96, pp. 607-609. Date of Electronic Publication: 2020 May 11.
Publication Year :: 2020
Abstract: Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).<br /> (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Subjects :: Betacoronavirus
COVID-19
Cytokine Release Syndrome drug therapy
Cytokine Release Syndrome virology
Humans
Male
Middle Aged
Pandemics
SARS-CoV-2
COVID-19 Drug Treatment
Coronavirus Infections drug therapy
Interleukin 1 Receptor Antagonist Protein therapeutic use
Pneumonia, Viral drug therapy

Language :: English
ISSN :: 1878-3511
Volume :: 96
Database :: MEDLINE
Journal :: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Publication Type :: Academic Journal
Accession number :: 32437934
Full Text :: https://doi.org/10.1016/j.ijid.2020.05.026